CASE REPORT

The First Case of Metastatic Pancreatic Leiomyosarcoma Derived from the Urinary Bladder Diagnosed Using an Endoscopic Ultrasound-guided Fine-needle Biopsy

Ayana Ishizaki, Kosuke Okuwaki, Mitsuhiro Kida, Hiroshi Imaizumi, Tomohisa Iwai, Hiroshi Yamauchi, Toru Kaneko, Rikiya Hasegawa, Hironori Masutani, Masayoshi Tadehara, Kai Adachi, Masafumi Watanabe, Takahiro Kuros, Akihiro Tamaki and Wasaburo Koizumi

Abstract:
We herein report the first case of metastatic pancreatic leiomyosarcoma derived from the urinary bladder diagnosed by an endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) in a 65-year-old woman. The patient had undergone total cystectomy for bladder leiomyosarcoma. Four years thereafter, a nodule was observed in her left lung on chest computed tomography. Suspecting primary lung cancer, pulmonologists at our hospital recommended a thoracoscopic lung biopsy, which the patient refused. Five years post-cystectomy, fluorodeoxyglucose positron emission tomography revealed enlargement of the left lung nodule and a new mass in the pancreatic head. She was referred to our department for the pathological diagnosis of a pancreatic head mass by an EUS-FNB. The EUS-FNB yielded adequate pancreatic tissue for an immunohistochemical analysis. A diagnosis of metastatic pancreatic lesion originating from the urinary bladder was made. In atypical pancreatic tumors, the utilization of an EUS-FNB and immunohistochemical analysis can help establish an accurate diagnosis.

Key words: pancreas, leiomyosarcoma, neoplasm metastasis, urinary bladder neoplasms

(Intern Med 60: 1377-1381, 2021)
(DOI: 10.2169/internalmedicine.6143-20)

Introduction

The use of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has increased rapidly since it was first reported by Vilmann et al. (1) in 1992. It is currently considered a safe, minimally invasive, and reliable technique for pathologically examining solid masses. The main target lesions of EUS-FNA are upper abdominal masses, such as pancreatic neoplasms, upper gastrointestinal subepithelial lesions, and mediastinal neoplasms. Recent advances in EUS-FNA have made the pathological diagnosis of previously undiagnosed diseases possible without surgical resection. Furthermore, recently developed fine-needle biopsy (FNB) needles are able to collect a sufficient volume of sample to establish a diagnosis histologically. These needles have attracted substantial attention owing to their advanced diagnostic capabilities and superiority relative to conventional FNA needles (2-8).

We herein report our experience with a patient who had metastatic leiomyosarcoma of the pancreas that was diagnosed by an EUS-FNB. To our knowledge, this is the first case report describing the diagnosis of metastatic pancreatic leiomyosarcoma derived from the urinary bladder by an EUS-FNB.

Case Report

A 65-year-old woman underwent total (radical) cystectomy for bladder leiomyosarcoma. At the four-year follow-up, chest computed tomography (CT) showed a pulmonary nodule in her left lung. Suspecting primary lung cancer, pul-
monologists at our hospital recommended a thorascoscopic lung biopsy, which the patient refused.

Five years post-cystectomy, an intracranial tumor was observed on CT, which had been performed to investigate complaints of paresthesia of her right arm and leg. Doctors diagnosed her with an intracranial metastasis from pulmonary carcinoma, and she underwent radiation therapy. Fluorodeoxyglucose positron emission tomography (FDG-PET) performed around the same time revealed enlargement of the left lung nodule and a new mass in the pancreatic head. She was referred to our department for a pathological diagnosis of the pancreatic head mass by an EUS-FNB.

The medical history of the patient and her family was unremarkable. In addition, the only unusual physical finding was right-sided paresis. Her alkaline phosphatase levels were slightly elevated. She tested negative for all tumor markers examined (carcinoembryonic antigen, carbohydrate antigen 19-9, duke pancreatic monoclonal antigen type 2, progastrin-releasing peptide, and squamous cell carcinoma). An irregular 35-mm nodule was noted on chest CT with a spiculated margin in the upper field of the left lung (Fig. 1). A 9-mm, low-density area with relatively clear margins was observed in the arterial phase of abdominal enhanced CT (Fig. 4D). The obtained histological sections are shown in Fig. 5. Proliferation of spindle cells with nuclear atypia was noted on Hematoxylin and Eosin (H&E) stained sections. In the immunohistochemical analysis, neoplastic cells were positive for α-smooth muscle actin (αSMA) and vimentin and negative for AE1/3, CD34, S-100 protein, c-kit, and discovered on GIST1. The cells had an MIB-1 labeling index of 20%. These findings indicated the mass to be a malignant mesenchymal tumor with smooth muscle differentiation and high proliferative potential, leading us to diagnose the patient with a leiomyosarcoma (metastatic recurrence of bladder leiomyosarcoma).

After the EUS-FNB, spindle cells were also observed in tissue collected from the pulmonary lesion via a transbronchial route, which tested negative for TTF-1, Napsin A, p40, and CK5/6. Based on the findings of the immunohistochemical analysis, we concluded that the nodule was most likely a metastatic lesion originating from urinary bladder leiomyosarcoma.

**Figure 1.** Computed tomography of the chest. An irregular nodular lesion with spiculated margins, 28 mm in size, is visible in the upper left lung (arrowhead).

**Figure 2.** Computed tomography of the abdomen. A 9-mm, low-density area with relatively clear margins was observed in the arterial phase of abdominal enhanced CT (arrowhead).

**Discussion**

Non-epithelial tumors account for less than 5% of bladder malignancies, and leiomyosarcomas are even rarer, accounting for only 0.1% of bladder malignancies (9). In a study of postoperative outcomes of bladder leiomyosarcoma, Spiess et al. noted local recurrence in 16% of cases and distant metastases in 53%, most frequently to the lungs, bones, liver, or brain (10). However, the occurrence of metastatic pancreatic cancer is extremely rare. Indeed, in a review conducted in 2004 using data collected from records of autopsy records and surgical resections, Amsay et al. observed secondary tumors of the pancreas in 1.6% and 3.9% of such cases, respectively (11). According to Minni et al., the primary origins of metastatic pancreatic cancer are most frequently renal cell carcinoma (45%), followed by lung carcinoma (14.7%), breast carcinoma (7.5%), and colonic carcinoma (6.6%) (12). In addition, Adler et al., in a review of 399
Figure 3. Fluorodeoxyglucose (FDG) positron emission tomography. A: An increased FDG uptake is apparent in the 35-mm mass in the upper left lung. B: An increased FDG uptake is visible in the micronodular lesion at the pancreatic head (arrowhead).

Figure 4. Endosonography and EUS-guided fine-needle biopsy findings. A: A 10-mm mass is visible in the pancreatic head, characterized by a distinct border, irregular margin, and uniformly hyperechoic interior. B: A poor blood flow is indicated by the weak Doppler ultrasound signal. C: On contrast-enhanced EUS, the mass presents with an avascular pattern in the initial phase. D: The mass is punctured by a 22-gauge biopsy needle. EUS: endoscopic ultrasound.
autopsy cases as metastases from other organs, including a single case of urinary bladder origin (11). However, their work did not include any information on the histopathology. A literature search using PubMed/MEDLINE indicated that cases of metastatic pancreatic leiomyosarcoma derived from the urinary bladder had not been reported previously. This is the first case of metastatic pancreatic leiomyosarcoma derived from the urinary bladder diagnosed by an EUS-FNB.

In this case, the nodule was observed in the patient’s lung, an area prone to postoperative (metastatic) recurrence of urinary bladder leiomyosarcoma, before the appearance of the pancreatic mass. Therefore, the most plausible diagnosis seemed to be metastatic lung and pancreatic cancer originating from primary bladder leiomyosarcoma. However, the CT findings in our patient were consistent with primary lung cancer. It is well known that primary lung cancer frequently metastasizes to the pancreas, and this led us to consider primary lung cancer along with metastatic pancreatic cancer in our differential diagnosis. We concluded that pancreatic duct carcinoma was unlikely for several reasons. First, her blood biochemical profile was negative for all tumor markers specific to this condition. Second, there was no associated dilation caudal to the mass of the main pancreatic duct. Finally, her contrast EUS presentation lacked hypoenhancement, a characteristic feature of pancreatic duct carcinoma proposed by Kitano et al. (14). Eventually, using a biopsy needle, a method which is reportedly useful for making a diagnosis (2-8), we collected sizable quantities of tumor tissue, allowing us to perform a wide variety of immunostaining tests needed for a differential diagnosis. Pancreatic carcinoma was ruled out based on the proliferation of spindle cells with nuclear atypia identified by H&E staining. In addition, the tumor cells were negative for cytokeratin (AE1/AE3) and positive for vimentin and αSMA on immunohistochemistry. We diagnosed the mass as a leiomyosarcoma: a mesenchymal malignancy exhibiting smooth muscle differentiation and a high proliferative potential, confirmed based on an MIB-1 proliferation index of 20%. Despite the small size of the tumor, the EUS-FNB facilitated the collection of a sufficient sample to obtain a pathological diagnosis by an immunohistochemical analysis. Previous studies have reported that the recently developed biopsy needle enables the collection of more tissue than previously existing puncture needles (15). In line with this, we recommend using a biopsy needle for the diagnosis of small tumors, such as the one reported in the present case.

Of note, spindle cells were also observed in tissue collected from the pulmonary lesion via a transbronchial route, and these tested negative for both adenocarcinoma and squamous cell carcinoma markers. The grade of nuclear

Figure 5. Histological sections of specimens obtained by an EUS-FNB. A: 100× magnification of a histological specimen of the tumor stained with Hematoxylin and Eosin (H&E) staining. Spindle-shaped tumor cells with nuclear variants were present. B: 200× magnification of a histological specimen of the tumor stained with H&E staining. C: Staining for AE1/3 was negative (100× magnification). D: Staining for vimentin was positive (100× magnification). E: Staining for α-smooth muscle actin was positive (100× magnification). F: The MIB1-index was 20% (100× magnification). EUS-FNB: endoscopic ultrasound-guided fine-needle biopsy.
Pathological findings, which may help establish a diagnosis and immunohistochemical analysis can provide accurate diagnosis confirmed by an EUS-FNB, the patient in present case is not feasible in the present case, as the patient had moved to a different country.

Metastatic pancreatic tumors are often discovered at an end-of-life stage when malignancies spread throughout the body. However, some patients with these malignancies remain physically active, which is an important criterion to be eligible for surgical resection or chemotherapy. Based on the accurate diagnosis confirmed by an EUS-FNB, the patient in the present case was administered doxorubicin chemotherapy (75 mg/m²). When practitioners encounter an atypical pancreatic tumor, the proactive performance of an EUS-FNB and immunohistochemical analysis can provide accurate pathological findings, which may help establish a diagnosis that can guide and result in the proper treatment of such malignancies.

The authors state that they have no Conflict of Interest (COI).

References

1. Vilmann P, Jacobsen GK, Henriksen FW, Hancke S. Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease. Gastrointest Endosc 38: 172-173, 1992.
2. Bang JY, Hebert-Magee S, Hasan MK, Navaneethan U, Hawes R, Varadarajulu S. Endoscopic ultrasonography-guided biopsy using a Franseen needle design: initial assessment. Dig Endosc 29: 338-346, 2017.
3. Bang JY, Hebert-Magee S, Navaneethan U, Hasan MK, Hawes R, Varadarajulu S. Randomized trial comparing the Franseen and Fork-tip needles for EUS-guided fine-needle biopsy sampling of solid pancreatic mass lesions. Gastrointest Endosc 87: 1432-1438, 2018.
4. Sugiura R, Kuwatani M, Yane K, et al. Prospective, multicenter, observational study of tissue acquisition through EUS-guided fine-needle biopsy using a 25 G Franseen needle. Endosc Ultrasound 8: 321-328, 2019.
5. Trindade AJ, Benias PC, Alshelleh M, et al. Fine-needle biopsy is superior to fine-needle aspiration of suspected gastrointestinal stromal tumors: a large multicenter study. Endosc Int Open 7: E931-E936, 2019.
6. Asokkumar R, Yung Ka C, Loh T, et al. Comparison of tissue and molecular yield between fine-needle biopsy (FNB) and fine-needle aspiration (FNA): a randomized study. Endosc Int Open 7: E955-E963, 2019.
7. Matsuno J, Ogura T, Kurisu Y, et al. Prospective comparison study of Franseen needle and standard needle use for pancreatic lesions under EUS guidance. Endosc Ultrasound 8: 412-417, 2019.
8. Okuwaki K, Masutani H, Kida M, et al. Diagnostic efficacy of white core cutoff lengths obtained by EUS-guided fine-needle biopsy using a novel 22 G Franseen biopsy needle and sample isolation processing by stereomicroscopy for subepithelial lesions. Endosc Ultrasound 9: 187-192, 2020.
9. Hamadalla NV, Rifat UN, Safi KC, Mohammed M, Abu-Farsakh H. Leiomyosarcoma of the urinary bladder: a review and a report of two further cases. Arab J Urol 11: 159-164, 2013.
10. Spieß PE, Kassouf W, Steinberg JR, et al. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol 25: 38-45, 2007.
11. Amdal A, Andea A, Basturk O, Kilinc N, Nassar H, Cheng JD. Secondary tumors of the pancreas: an analysis of a surgical and autopsy database and review of the literature. Virchows Arch 444: 527-535, 2004.
12. Minni F, Casadei R, Perenze B, et al. Pancreatic metastases: observations of three cases and review of the literature. Pancreatology 4: 509-520, 2004.
13. Adler H, Redmond CE, Heneghan HM, et al. Pancreatectomy for metastatic disease: a systematic review. Eur J Surg Oncol 40: 379-386, 2014.
14. Kitano M, Kado M, Yamao K, et al. Characterization of small solid tumors in the pancreas: the value of contrast-enhanced harmonic endoscopic ultrasonography. Am J Gastroenterol 107: 303-310, 2012.
15. Mukai S, Itoi T, Yamaguchi H, et al. A retrospective histological comparison of EUS-guided fine-needle biopsy using a novel Franseen needle and a conventional end-cut type needle. Endosc Ultrasound 8: 50-57, 2019.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).